Full-Time
Develops wearable defibrillator for cardiac arrest
$230k - $240k/yr
Senior
No H1B Sponsorship
San Carlos, CA, USA
This position is based in our Redwood City office. No relocation assistance available.
Upload your resume to see how it matches 11 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Element Science focuses on developing health technology aimed at preventing sudden cardiac arrest. Its main product, Jewel®, is a wearable defibrillator that offers continuous protection for users at risk of cardiac events. Although Jewel® is not yet available for sale in the U.S., it represents a significant advancement in medical devices. The company targets individuals who are at risk, which includes millions globally, and plans to generate revenue through the sale of these devices to consumers, healthcare providers, and insurance companies. Element Science distinguishes itself from competitors by not only prioritizing innovative medical solutions but also by fostering a diverse and inclusive workplace culture. The company's goal is to enhance the lives of those at risk of sudden cardiac arrest while promoting diversity, equity, and inclusion within its team.
Company Size
51-200
Company Stage
Series C
Total Funding
$183.1M
Headquarters
San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Stock Options
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
FSA (Flexible Spending Accounts)
HSA (Health Savings Account)
Employee Assistance Program through PEO
Element Science, an innovative health technology company pioneering a digital wearable platform that monitors and protects high-risk cardiovascular patients, announces that its Jewel(R) Wearable Patch Cardioverter Defibrillator (Jewel) has received the prestigious Red Dot Design Award.
With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company's first Head of Commercial
Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs. While these garment-based WCDs have demonstrated the ability to treat sudden cardiac arrest (SCA), a leading cause of death in the United States and in Europe, challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption.The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, conducted in Prague, Czech Republic, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients presented at the American Heart Association’s 2023 Annual Scientific Sessions demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device (www.ElementScience.com/ide-study/ ).Dr. Uday N
SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced that Trish Howell has been appointed as the Company’s new Chief Operating Officer, effective October 17, 2022. “ Ms. Howell is a transformational leader who has excelled in her positions prior to joining Element Science. As an innovative and seasoned executive, she expands the capabilities of our leadership team at an inflection point of our growth. Her experience in building successful commercial operations at medical device companies gives her a critically valuable perspective that will be an indispensable asset as we look forward to commercializing our technology and expanding our pipeline of products,” said Uday N. Kumar, MD, Founder, President and CEO
SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced that Trish Howell has been appointed as the Company’s new Chief Operating Officer, effective October 17, 2022. “ Ms. Howell is a transformational leader who has excelled in her positions prior to joining Element Science. As an innovative and seasoned executive, she expands the capabilities of our leadership team at an inflection point of our growth. Her experience in building successful commercial operations at medical device companies gives her a critically valuable perspective that will be an indispensable asset as we look forward to commercializing our technology and expanding our pipeline of products,” said Uday N. Kumar, MD, Founder, President and CEO